These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 17507664)

  • 21. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
    Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
    J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
    Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
    Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.
    Carbone A; Dolcetti R; Gloghini A; Maestro R; Vaccher E; di Luca D; Tirelli U; Boiocchi M
    Hum Pathol; 1996 Feb; 27(2):133-46. PubMed ID: 8617454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
    Pule MA; Savoldo B; Myers GD; Rossig C; Russell HV; Dotti G; Huls MH; Liu E; Gee AP; Mei Z; Yvon E; Weiss HL; Liu H; Rooney CM; Heslop HE; Brenner MK
    Nat Med; 2008 Nov; 14(11):1264-70. PubMed ID: 18978797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
    Huls MH; Rooney CM; Heslop HE
    Acta Haematol; 2003; 110(2-3):149-53. PubMed ID: 14583675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexpression of major histocompatibility complex class I and LMP1 in Epstein-Barr virus-positive Hodgkin's lymphoma in a pediatric age group.
    Aybar A; Krause JR
    Microsc Res Tech; 2005 Nov; 68(3-4):247-9. PubMed ID: 16276512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
    Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
    J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges of driving CD30-directed CAR-T cells to the clinic.
    Grover NS; Savoldo B
    BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
    Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
    Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.
    Hong B; Peng G; Berry L; Gottschalk S; Jung JU; Chen SY; Huang XF
    Gene Ther; 2012 Aug; 19(8):818-27. PubMed ID: 22052242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
    Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
    Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy targeting EBV-expressing lymphoproliferative diseases.
    Bollard CM; Cooper LJ; Heslop HE
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):405-20. PubMed ID: 18790446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
    Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
    Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.
    Kim LH; Eow GI; Peh SC; Poppema S
    Pathology; 2003 Oct; 35(5):428-35. PubMed ID: 14555388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
    Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
    J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.